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Abstract 
Background: Certain Chinese medicine (CM) herbs and acupuncture may protect against Alzheimer’s disease (AD). 
However, there is a lack of research regarding the use of CM in patients with AD. The aim of this study was to investi‑
gate CM usage patterns in patients with AD, and identify the Chinese herbal formulae most commonly used for AD.
Methods: This retrospective, nationwide, population‑based cohort study was conducted using a randomly sampled 
cohort of one million patients, selected from the National Health Insurance Research Database between 1997 and 
2008 in Taiwan. CM use and the top ten most frequently prescribed formulae for treating AD were assessed, including 
average formulae dose and frequency of prescriptions. Demographic characteristics, including sex, age and insurance 
level were examined, together with geographic location. Existing medical conditions with the behavioral and psycho‑
logical symptoms of dementia, and medications associated with CM were also examined. Factors associated with CM 
use were analyzed by multiple logistic regressions.
Results: The cohort included 1137 newly diagnosed AD patients, who were given conventional treatment for AD 
between 1997 and 2008. Among them, 78.2 % also used CM treatments, including Chinese herbal remedies, acu‑
puncture and massage manipulation. Female patients (aOR 1.57 with 95 % CI 1.16–2.13) and those living in urban 
areas (aOR 3.00 with 95 % CI 1.83–4.90 in the middle of Taiwan) were more likely to use CM. After adjusting for demo‑
graphic factors, AD patients suffering from the behavioral and psychological symptoms of dementia were more likely 
to seek CM treatment than those with no symptoms (aOR 2.26 with 95 % CI 1.48–3.43 in patients suffering more than 
three symptoms). Bu‑Zhong‑Yi‑Qi‑Tang and Ji‑Sheng‑Shen‑Qi‑Wan were the two formulae most frequently prescribed 
by CM practitioners for treating AD.
Conclusion: Most people with AD who consumed herbal products used supplement qi, nourish the blood, and quiet 
the heart spirit therapy as complementary medicines to relieve AD‑related symptoms, in addition to using standard 
anti‑AD treatments.
© 2016 Lin et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Alzheimer’s disease (AD) is a neurodegenerative disease 
characterized by substantial memory impairment, apha-
sia, apraxia, agnosia and function disturbance [1]. AD 
is the most common cause of dementia in older people 
and accounts for 60–80 % of reported dementia cases in 
the World [2]. Although psychosocial and pharmacologic 
interventions can be effective for alleviating AD-related 
symptoms [3], there is currently no curative treatment 
for AD.
It has been reported that some Chinese herbs may pro-
tect brain cells against AD [4, 5]. However, clinical evi-
dence regarding the efficacy of Chinese medicine (CM) 
for treating AD is limited. This study therefore aims to 
investigate the extent to which CM is used by patients 
suffering from AD, and to identify the most common 
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Methods
This study was approved by the Taipei City Hospital 
Institutional Review Board under study number TCH-
IRB-1020816-E (Additional file  1) and National Health 
Research Institutes under study number NHIRD-103-091 
(Additional file 2). The research and associated reporting 
have been conducted in accordance with conventional 
ethical principles to protect the identities of the patients 
involved.
Data resources
This retrospective, nationwide, population-based cohort 
study was conducted using a randomly sampled cohort of 
one million patients, selected from the National Health 
Insurance Research Database (NHIRD) between 1997 
and 2008 in Taiwan. The National Health Insurance 
(NHI) system covers over 97 % of the population of Tai-
wan and provides full reimbursement to its members 
for treatments based on CM, including Chinese herbal 
products, acupuncture, moxibustion and traumatol-
ogy manipulative therapies. The NHI also holds all of 
the medical records for CM treatments prescribed by 
licensed CM practitioners [6].
One million patient records were randomly selected 
from those of the 23 million Taiwanese people currently 
insured under the NHI system. No significant differences 
were observed in the demographic distribution between 
the random sample and the original NHIRD. The medi-
cal records used in this study were collected for the dates 
between the 1st of January, 1996 and the 31st of Decem-
ber, 2008. The NHIRD database contained complete data 
pertaining to clinical visits, and hospitalization records, 
including visit date, hospital, physician specialist, major 
diagnoses and the dosage and frequency of any medicines 
prescribed. The Bureau of National Health Insurance 
requires physicians to record major diagnoses according 
to the format described in the International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM).
Study sample
Figure 1 shows a flowchart describing of the sample selec-
tion process. First, all patients without dementia (ICD-9 
codes: 290.0, 290.1, 290.2, 290.3, 290.4, 294.1, 294.2 and 
331) were excluded (n = 965,572). Second, we excluded 
patients with a dementia diagnosis not made by a quali-
fied neurologist or psychologist (n  =  13,403), along 
with patients that did not receive anti-AD treatment 
(n  =  19,822). Doctors in Taiwan are requested by the 
Bureau of National Health Insurance to only prescribe 
anti-AD drugs to patients that fulfill the criteria outlined 
by the National Institute of Neurological and Communi-
cative Disorders and Stroke (NINCDS), the Alzheimer’s 
Disease and Related Disorders Association (ADRDA) or 
the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM IV-TR). Finally, cases of AD diagnosed before 
the end of 1996 were excluded from the current study, as 
well as those without complete NHI reimbursement data 
(n  =  66) to ensure that all of the patients represented 
newly diagnosed cases of AD. Upon completion of this 
exclusion process, we had a study cohort consisting of 
1137 patients.
Study variables
Several demographic factors were selected from previ-
ous studies [7]. The patients were categorized into six 
different age groups:  <45, 45–54, 55–64, 65–74, 75–84 
and  ≥85  years of age. The geographic locations of the 
patients were sorted into seven different regions with 
similar regional environments: Taipei City and Kaohsi-
ung City, the Northern, Central, Eastern and Southern 
regions of Taiwan, and the outlying islands.
The amount of money to which each patient was 
insured was divided into four levels: 0, 1–19,999, 20,000–
39,999 and  >40,000 new Taiwanese dollars. The “0” 
insured level included unemployed and retired patients, 
for whom the insurance costs were covered by the gov-
ernment or other family members.
One million random sample of NHIRD
N = 1,000,000
CM non-use
n = 248 (21.8%)
CM use
n = 889 (78.2%)
Exclusion of paents without 
demena diagnosis, 
N = 965,572
Patients with demena, 
N = 34,428
Demena paents diagnosed by a 
neurologist or psychologist doctor, 
N = 21,025
Paents approvad for Alzheimer's 
medicaon by NHI,
N = 1,203
New cases of Alzheimer's disease, 
N = 1,137
Exclusion of paents which are 
not diagnosis by a neurologist or 
psychologist doctors, 
N = 13,403
Exclusion of paents not taking 
an-Alzheimer's medicaon, 
N = 19,822
Exclusion of cases of Alzheimer's 
disease diagnosed before the 
end of 1996 and with missing 
informaon concerning age, 
N = 66
Fig. 1 Flow chart detailing the recruitment of subjects from random 
sample of one million patients from the NHIRD between 1997 and 
2008
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The NHIRD database was searched for diagnosis and 
treatment records relating to the behavioral and psy-
chological symptoms of dementia (BPSD), including 
delirium (ICD9 codes: 290.11, 290.3 and 290.41), delu-
sions (ICD9 codes: 290.20, 290.12 and 290.42), depres-
sion (ICD9 codes: 290.13, 290.21 and 290.43), sleep 
disturbances (ICD9 codes: 780.5 and 307.4), hallucina-
tion (ICD9 codes: 7801, 2913 and 2928) and behavioral 
disturbances (ICD9 codes: 294.11 and 294.21). The reim-
bursement database contains all of the important details 
relating to the prescription of conventional medicines for 
treating AD. The types of prescription drugs used to treat 
AD were categorized as follows: donepezil, rivastigmine, 
galantamine, memantine, deprenyl, antipsychotic, anti-
manic, anxiolytic and antidepressant.
The comorbidities of the patients were categorized 
using the icd-9-cm codes. Notably, the results of previous 
studies have shown that some comorbidities, including 
diabetes mellitus (icd9 codes: 249 and 250), hypertension 
(icd9 codes: 401–405), hyperlipidemia (icd9 codes: 272), 
chronic kidney disease (icd9 codes: 585, 586 and 588), 
cerebral vascular accident (icd9 codes: 430–438) and ath-
erosclerosis (icd9 codes: 440), can affect the prognosis 
and treatment of patients diagnosed with AD.
Chinese medicine treatment
Chinese herbal products (CHPs) composed of one 
or more herbs (i.e., herbal formulae), which are cov-
ered by the NHI system, are more widely adopted by 
Taiwanese patients than any other form of CM. [8] 
Information pertaining to CHPs was obtained from 
the Department of Chinese Medicine and Pharmacy 
(DCMP), Ministry of Health and Welfare, Taiwan, 
including the name and ingredients of their herbal for-
mula, as well as their pharmaceutical effects, DCMP 
manufacturing code and manufacturer. CHPs with the 
same good manufacturing practices and DCMP stand-
ards were sorted into the same group [9]. The acu-
puncture therapy including acupoint and frequency 
and massage manipulation and treatment position 
were also record by the NHI system.
Statistical analysis
The factors associated with the CM treatments used in 
the current study were analyzed using multiple logis-
tic regression with a significance level of α  =  0.05. 
An odds ratio was used to quantify the relationships 
between the different conditions and CM use. All 
of the odds ratios were adjusted based on the demo-
graphic factors described above. Version 9.3 of the SAS 
statistical analysis software (version 9.4; SAS Institute 
Inc., Cary, NC, USA) was used for data management 
and analysis.
Results
The NHIRD of outpatient claims contained information 
pertaining to the claims of 1137 patients with AD from 
1997 to 2008. Among them, 889 (78.2  %) AD patients 
used CM outpatient services. The mean age of non-CM 
users was slightly higher than that of CM users.
Table  1 shows details concerning the demographic 
and medication distributions of the CM and non-CM 
users. After adjusting for demographic factors, the 
results clearly showed that AD patients suffering from 
one or more BPSD (one symptom: OR =  0.90, 95  % CI 
0.57–1.44; two symptoms: OR = 1.94, 95 % CI 1.24–3.05; 
three or more symptoms: OR = 2.26, 95 % CI 1.48–3.43) 
were more likely to seek CM treatment than those with 
no BPSD. Female patients and those living in urban 
areas were more likely to seek CM treatment than male 
patients and those living in rural areas. No discernible 
difference was observed in CM use between AD patients 
suffering from one or more comorbidities (one: OR = 1.1, 
95 % CI 0.47–2.58; two: OR =  0.91, 95 % CI 0.41–2.01; 
and three or more types: OR = 1.76, 95 % CI 0.83–3.74) 
and those with no comorbidity.
Analyses of the major disease categories for all CM vis-
its are summarized in Table  2. These results show that 
18,138 (73.3 %) visits were treated with prescribed CHPs, 
whereas the remaining visits were treated with acu-
puncture and traumatology manipulative therapies. AD 
patients tended to use CHPs rather than acupuncture. 
“Symptoms, signs and ill-defined conditions” was cited 
as the most common reason for using CM (20.2 %, 5011 
visits), followed sequentially by “diseases of the muscu-
loskeletal system and connective tissue” (20.0  %, 4962 
visits), “diseases of the respiratory system” (14.3 %, 3542 
visits) and “diseases of the digestive system” (12.2 %, 3024 
visits). Of the AD patients evaluated in the current study, 
9.3  % sought CMs with the aim of treating their “men-
tal disorders, diseases of the nervous system and sense 
organs”.
Table 3 shows the details of the CHPs most frequently 
prescribed by CM practitioners for treating mental dis-
orders and diseases of the nervous system. The results 
show that Bu-Zhong-Yi-Qi-Tang was the most frequently 
prescribed CHP, followed by Ji-Sheng-Shen-Qi-Wan, Ma-
Zi-Ren-Wan and Tian-Wang-Bu-Xin-Dan. The potential 
effects of the herbs contained in the 10 most common 
formulae are shown in Table  4. It is noteworthy that 
several herbs, including Ginseng Radix (Ren-Shen) and 
Angelicae Sinensis Radix Integra (Dang-Gui), appeared 
repeatedly in formulae reported to be effective against 
AD. Table  5 shows that 77.1  % of the AD patients con-
sumed Bu-Zhong-Yi-Qi-Tang during the period covered 
by the current study. After adjusting for demographic 
factors, the results revealed that female AD patients 
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(OR = 1.23, 95 % CI 1.04–1.57) were more likely to con-
sume Bu-Zhong-Yi-Qi-Tang than male patients.
Discussion
To the best of our knowledge, this study was the first 
reported one using a random national-level sample to 
document the usage characteristics of traditional Chinese 
medicines in AD patients. The incidence of AD was less 
than 0.3 % in people aged 55–64 years, with the incidence 
increasing with increasing age. In people aged 85 years or 
older, the incidence was found to be 17.9 %, which is low 
compared with results of previous surveys [10, 11]. Nota-
bly, all of the patients described in the current study were 
newly diagnosed with AD by board-certified neurologists 
or psychiatrists and selected from a random sample of 
one million patients. Furthermore, these patients were 
selected from the insured general population of Taiwan 
and the rate of insured people was consistently above 
Table 1 Demographic and  medication characteristics 
and  results of  multiple logistic regression for  CM use 
among patients with Alzheimer’s disease
Characteristics CMa users CMa non-users aORb (95 % CIc)
No. of cases 889 (78.2 %) 248 (21.8 %)
Age at diagnosis (incidence rate)
 <45 (0.001 %) 7 (0.8 %) 2 (0.8 %) 0.78 (0.15–4.05)
 45–54 (0.036 %) 27 (3 %) 2 (0.8 %) 3.64 (0.80–16.53)
 55–64 (0.246 %) 115 (12.9 %) 27 (10.9 %) 1
 65–74 (1.185 %) 309 (34.8 %) 92 (37.1 %) 0.74 (0.45–1.22)
 75–84 (7.105 %) 381 (42.9 %) 107 (43.1 %) 0.83 (0.51–1.36)
 ≥85 (17.942 %) 50 (5.6 %) 18 (7.3 %) 0.61 (0.30–1.24)
Mean years 72.8 73.8
Sex
 Female (0.13 %) 530 (59.6 %) 121(48.8 %) 1.57 (1.16–2.13)
 Male (0.10 %) 359 (40.4 %) 127 (51.2 %) 1
Insured region
 Taipei city 137 (15.4 %) 61 (24.6 %) 1
 Kaohsiung city 71 (8 %) 14 (5.6 %) 2.38 (1.24–4.57)
 Northern Taiwan 200 (22.5 %) 58 (23.4 %) 1.65 (1.07–2.54)
 Middle Taiwan 209 (23.5 %) 32 (12.9 %) 3.00 (1.83–4.90)
 Southern Taiwan 240 (27 %) 78 (31.5 %) 1.39 (0.91–2.12)
 Eastern Taiwan 21 (2.4 %) 4 (1.6 %) 2.48 (0.80–7.64)
 Outlying island 11 (1.2 %) 1 (0.4 %) 4.98 (0.61–40.51)
Insured amount (NT$d)
 0 353 (39.7 %) 94 (37.9 %) 0.99 (0.68–1.45)
 1–19,999 486 (54.7 %) 140 (56.5 %) 1
 20,000–39,999 32 (3.6 %) 8 (3.2 %) 0.90 (0.38–2.15)
 ≥400,000 18 (2 %) 6 (2.4 %) 0.77 (0.28–2.13)
Numbers of anti‑Alzheimer’s or BPSD drugs
 1 28 (3.1 %) 8 (3.2 %) 1
 2 145 (16.3 %) 51 (20.6 %) 0.81 (0.35–1.90)
 3 318 (35.8 %) 87 (35.1 %) 1.04 (0.46–2.37)
 ≥4 398 (44.8 %) 102 (41.1 %) 1.12 (0.49–2.52)
Numbers of dementia BPSDe
 0 102 (11.5 %) 46 (18.5 %) 1
 1 122 (13.7 %) 61 (24.6 %) 0.90 (0.57–1.44)
  Delirium 4 3
  Delusions 13 7
  Depression 18 12
  Behavioral distur‑
bance
4 2
  Sleep disturbances 83 37
  Hallucination 0 0
 2 250 (28.1 %) 58 (23.4 %) 1.94 (1.24–3.05)
  Delirium + delu‑
sions
8 7
  Delirium + depres‑
sion
2 1
  Delirium + behav‑
ioral
0 0
  Delirium + sleep 12 6
a  CM refers to Chinese medicine
b  aOR refers to adjust odds ratio
c  CI refers to confidence interval
d  NT$ refers to new Taiwan dollars, of which 1 US $ = 30 NT$
e  BPSD refers to behavioral and psychological symptoms of dementia
Table 1 continued
Characteristics CMa users CMa non-users aORb (95 % CIc)











  Delusions + sleep 21 11







  Depression + sleep 21 8
  Depression + hal‑
lucination
0 1
  Behavioral + sleep 6 0
  Behavioral + hal‑
lucination
0 0
  Sleep + hallucina‑
tion
169 22
 ≥3 415 (46.7 %) 83 (33.5 %) 2.26 (1.48–3.43)
Numbers of comorbidity
 0 25 (2.81 %) 10 (4.03 %) 1
 1 74 (8.32 %) 27 (10.89 %) 1.1 (0.47–2.58)
 2 148 (16.7 %) 65 (26.21 %) 0.91 (0.41–2.01)
 ≥3 642 (72.2 %) 146 (58.87 %) 1.76 (0.83–3.74)
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97 % since 1997. The possibility of selection or recall bias 
could therefore be excluded.
More than 78 % of the AD patients in the cohort were 
used some form of CM during the 12  years covered by 
the current study. High accessibility and full coverage for 
CM through the NHI scheme in Taiwan could lead to an 
increase in CM use. Furthermore, several Chinese herbs 
may be effective as alternative therapies for treating AD 
and related disorders [12]. The current findings also show 
that women and those living in urban areas are more 
likely to use CM than men and patients living rural areas. 
Similar trends were reported previously [13].
BPSD relating to AD such as delusions, paranoia, hal-
lucinations and anxiety could lead to an increase in car-
egiver burden and accelerate the progression of AD [14]. 
AD patients suffering from one or more BPSD were more 
likely to use traditional CM than those with no BPSD. In 
addition, using anti-AD or BPSD drugs did not lead to a 
reduction in CM use. AD patients consumed herbal ther-
apies with the aim of relieving their AD-related symp-
toms, rather than using these treatments as alternatives 
to standard anti-AD treatments (i.e., herbal therapies 
were consumed as complementary medicines).
The category “symptoms, signs and ill-defined con-
ditions” was the most frequently cited diagnosis in the 
disease category for CM visits to classify the diagnosis 
pattern of CM. This phenomenon has also been observed 
in several other patient populations [15]. In addition, 
9.3 % of patients with AD in the “mental disorders, dis-
eases of the nervous system and sense organs” disease 
category had specifically sought out CM to treat their 
condition. CM treatments were generally used as adju-
vant therapies to relieve AD-related symptoms rather 
than being used as replacements for conventional anti-
AD treatment.
The category “diseases of the digestive system” was 
cited as one of the most common reasons for using 
CHPs (11.9 %, 2954 visits), with Ma-Zi-Ren-Wan being 
used to treat constipation [16]. Constipation is a com-
mon problem among geriatric patients, especially those 
with AD, in whom it is generally exacerbated by a lack 
of exercise or the side effects of anti-AD drugs [17]. 
Severe constipation in AD patients can lead to confu-
sion and symptoms of irritability or aggression because 
of the pain and discomfort associated with this condi-
tion [18]. Moreover, emodin, which is the major chemi-
cal constituent of Ma-Zi-Ren-Wan, protects the cortical 
neurons from β-amyloid-induced toxicity, representing a 
possible mechanism for treating AD [19]. In this study, 
Bu-Zhong-Yi-Qi-Tang was determined to be the most 
Table 2 Frequency distribution of  Chinese medicine visits by  major disease categories (according to  9th ICD codes) 
in Alzheimer’s patients from 1997 to 2008 in Taiwan
a  Other includes ICD-9-CM code range 740–779 and missing/error data
Major disease category ICD-9-CM code 
range
Number of visits (%)
Chinese herbal  
remedies
Acupuncture, or  
manipulative therapies
Total of CM
Infectious and parasitic diseases 001–139 42 (0.2) 5 (0.02) 47 (0.2)
Neoplasms 140–239 119 (0.5) 0 (0) 119 (0.5)
Endocrine, nutritional, blood and metabolic 
diseases, and immunity disorders
240–289 799 (3.2) 25 (0.1) 824 (3.3)
Mental disorders, diseases of the nervous system 
and sense organs
290–389 1901 (7.7) 389 (1.6) 2290 (9.3)
Diseases of the circulatory system 390–459 1006 (4.1) 162 (0.7) 1168 (4.7)
Diseases of the respiratory system 460–519 3449 (13.9) 93 (0.4) 3542 (14.3)
Diseases of the digestive system 520–579 2954 (11.9) 70 (0.3) 3024 (12.2)
Diseases of the genitourinary system 580–677 789 (3.2) 40 (0.2) 829 (3.3)
Diseases of the skin and subcutaneous tissue 680–709 327 (1.3) 9 (0.04) 336 (1.4)
Diseases of the musculoskeletal system and con‑
nective tissue
710–739 2016 (8.1) 2946 (11.9) 4962 (20.0)
Symptoms, signs, and ill‑defined conditions 780–799 3877 (15.7) 1134 (4.6) 5011 (20.2)
Injury and poisoning 800–999 77 (0.3) 852 (3.4) 929 (3.8)
Supplementary classification V01–V82, E800–
E999
0 (0) 4 (0.02) 4 (0.02)
Othersa 322 (1.3) 848 (3.4) 1170 (4.7)
Total 18,138 (73.3) 6613 (26.7) 24,751 (100.0)
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commonly prescribed formula, especially for female AD 
patients. Bu-Zhong-Yi-Qi-Tang led to elevated levels of 
dopamine and noradrenaline in the cortical tissues of 
mice, as well as improved attention, learning function 
and memory [20, 21]. Bu-Zhong-Yi-Qi-Tang was also 
used to treat elderly patients with weakness and fatigue 
[22].
Some frequently prescribed formulae have been 
reported to exhibit potentially positive effects on AD. 
For example, Sheng-Mai-San was reported to improve 
memory and decrease neuronal apoptosis in the hip-
pocampus [23]. Furthermore, Ji-Sheng-Shen-Qi-Wan 
and Liu-Wei-Di-Huang-Wan, which both belong to the 
Di-Huang-Wan group of formulae and share similar 
herbal components, were reported to increase cogni-
tive function after 2  months of treatment [24]. Some 
formulae were reported to show neuroprotective 
activity. For example, Tian-Ma-Gou-Teng-Yin led to a 
reduction in necrosis and apoptosis in neuronal cells 
through a variety of pharmacological effects, including 
anti-inflammatory, antioxidative and antiapoptotic 
activities [25]. Tao-Hong-Si-Wu-Tang exhibited neu-
roprotective effects against focal cerebral ischemia. 
Moreover, Gan-Mai-Da-Zao-Tang exhibited sedative 
and anti-anxiety effects in an animal model [26]. All of 
the aforementioned formulae, which are standard for-
mulae recommended by the DCMP, Ministry of Health 
and Welfare, Taiwan, must be modified by qualified 
CM practitioners in accordance with the principle of 
syndrome pattern identification as the basis for deter-
mining treatment.
Table 4 lists all of the herbs contained in the top ten 
most frequently prescribed formulae. Ginseng Radix 
(Ren-Shen), which is the major constituent herb in 
three of the top ten formulae, has been reported to 
show multiple effects against AD-related factors such 
as decreasing β-amyloid formation [27], increasing 
choline acetyltransferase [28] and forming a competi-
tive interaction with the N-methyl-D-aspartate receptor 
[29]. Ginseng Radix has also been reported to increase 
Table 3 Ten most commonly used herbal formulae prescribed by CM practitioners for treating mental disorders, diseases 
of the nervous system and sense organs (total prescriptions: 1901)
Herbal formu-
lae




















5.3 1.4 8.0 0.9 5.6 629 (33.1)
Ji‑Sheng‑Shen‑
Qi‑Wan
Life saver kidney 
Qi Pill
5.1 – – – – 538 (28.3)












3.9 – – – – 421 (22.1)
Sheng‑Mai‑San Pulse‑engender‑
ing powder

















3.5 – – 0.9 5.6 284 (14.9)
Tao‑Hong‑Si‑Wu‑
Tang




2.2 – – 0.4 2.5 258 (13.6)
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cognitive function [30]. Angelicae Sinensis Radix Integra 
(Dang-Gui) is the key component of Bu-Zhong-Yi-Qi-
Tang, Tian-Wang-Bu-Xin-Dan and Tao-Hong-Si-Wu-
Tang. An ethanolic extract of Dang-Gui enhanced 
cholinergic function [31], inhibited acetylcholinesterase 
[32], reduced β-amyloid associated neurotoxicity and 
decreased Tau protein hyperphosphorylation in a dose-
dependent manner [33].
There were several limitations associated with the cur-
rent study. First, health foods containing herbs, folk med-
icines and prescriptions from CM practitioners without a 
license from the Taiwanese authorities were not included 
in this study. Therefore CHP use may have therefore been 
underestimated. However, high healthcare insurance cov-
erage and low prices of government-approved CM led to 
a reduction in herbal folk medicine use. Second, it is not 
possible to draw any conclusions regarding the relation-
ship between cognitive function and CM use because of 
a general lack of detailed clinical data. This study focused 
primarily on a patient population with AD, the AD diag-
nosis was rigorously censored by the Bureau of National 
Health Insurance. Third, this study was conducted ret-
rospectively and did not include a randomized placebo 
group. Lastly, the CM formulae were modified according 
to the principle of syndrome differentiation.
Conclusions
Most people with AD who consumed herbal products 
used supplement qi, nourish the blood, and quiet the 
heart spirit therapy as complementary medicines to 
Table 4 Potential effects of  the herbs contained in  the ten most common formulae prescribed by  CM practitioners 
for treating Alzheimer’s disease
a  Formula containing a single herb that might promote the neurotransmitter acetylcholine
b  Formula containing a single herb that might inhibit the N-methyl-D-aspartate (NMDA) receptor
c  Formula containing a single herb that might reduce the β-amyloid
d  Formulae containing a single herb that might decrease the Tau protein
Herbal formulae Constituents
Bu‑Zhong‑Yi‑Qi‑Tanga, b, c, d Astragali Radix Cruda (Huang‑qi),Ginseng Radix (Ren‑shen)a, b, c, d, Glycyrrhizae Radix cum Liquido Fricta (Zhi‑gan‑cao), Atracty-
lodis MacrocephalaeRhizoma (Bai‑zhu), Angelicae Sinensis Radix Integra (Dang‑gui)a, c, d, CitriReticulatae Pericarpium (Chen‑
pi), Cimicifugae Rhizoma (Sheng‑ma), Bupleuri Radix (Chai‑hu), Zingiberis Rhizoma Recens (Sheng‑jiang), Jujubae Fructus 
(Da‑zao)
Ji‑Sheng‑Shen‑Qi‑Wana, c Rehmanniae Radix (Di‑huang), Poria cum (Fu‑ling)a, c, Corni Fructus (Shan‑zhu‑yu), Dioscoreae Rhizoma (Shan‑yao), Moutan 
Cortex (Mu‑dan‑pi), Alismatis Rhizoma (Ze‑xie), Aconiti Radix Lateralis (Fu‑zi), Cinnamomi Cortex (Rrou‑gui), Achyranthis 
Bidentatae Radix (Huai‑niu‑xi), Plantaginis Semen (Che‑qian‑zi)
Ma‑Zi‑Ren‑Wana, c Cannabis Fructus (Ma‑zi‑ren), Rhei Radix et Rhizoma (Da‑huang)c, Paeoniae Radix Alba (Bai‑shao)a, Aurantii Fructus Immaturus 
(Zhi‑shi), Magnoliae Officinalis Cortex (Hou‑po), Armeniacae Semen (Xing‑ren)
Tian‑Wang‑Bu‑Xin‑Dana, b, c, d Rehmanniae Radix (Di‑huang), Ginseng Radix (Ren‑shen)a, b, c, d, Polygalae Radix (Yuan‑zhi)c, Scrophulariae Radix(Xuan‑shen), 
Platycladi Semen (Bai‑zi‑ren), Platycodonis Radix (Jie‑geng), Asparagi Radix (Tian‑men‑dong), Salviae Miltiorrhizae Radix 
(Dan‑shen)c, Ziziphi Spinosi Semen (Suan‑zao‑ren), Ophiopogonis Radix (Mai‑men‑dong), Poria cum PiniRadice (Fu‑shen)a, c, 
Angelicae Sinensis Radix Integra (Dang‑gui)a, c, d, Schisandrae Fructus (Wu‑wei‑zi)
Gan‑Mai‑Da‑Zao‑Tang Glycyrrhizae Radix Cruda (Zhi‑gan‑cao),Jujubae Fructus (Da‑zao), Tritici Semen (Xiao‑mai)
Sheng‑Mai‑Sana, b, c, d Ginseng Radix (Ren‑shen)a, b, c, d,Ophiopogonis Radix (Mai‑men‑dong), Schisandrae Fructus (Wu‑wei‑zi)
Tian‑Ma‑Gou‑Teng‑Yina, c Gastrodiae Rhizoma (Tian‑ma)c, Uncariae Ramulus cum Uncis (Gou‑teng)a, Haliotidis Concha (Shi‑jue‑ming), Gardeniae 
Fructus(Shan‑zhi‑zi), Scutellariae Radix (Huang‑qin), Eucommiae Cortex (Du‑zhong), Loranthiseu Visci Ramus (Sang‑ji‑sheng), 
LeonuriHerba (Yi‑mu‑cao), PolygoniMultiflori Caulis (Ye‑jiao‑teng), Achyranthis Bidentatae Radix (Huai‑niu‑xi), Poria cum Pini 
Radice (Fu‑shen)a, c
Liu‑Wei‑Di‑Huang‑Wanc Rehmanniae Radix (Di‑huang), Poria cum (Fu‑ling)c, CorniFructus (Shan‑zhu‑yu), DioscoreaeRhizoma (Shan‑yao), Moutan 
Cortex (Mu‑dan‑pi), AlismatisRhizoma (Ze‑xie)
Qi‑Bao‑Mei‑Ran‑Dana, c, d PolygoniMultiflori Radix (He‑shou‑wu), AchyranthisBidentatae Radix (Huai‑niu‑xi), AngelicaeSinensis Radix Integra (Dang‑gui)a, c, 
d, Poria cum (Fu‑ling), Cuscutae Semen (Tu‑si‑zi), LyciiFructus (Gou‑qi‑zi), PsoraleaeFructus (Po‑gu‑zhi)
Tao‑Hong‑Si‑Wu‑Tanga, c, d Persicae Semen (Yao‑ren), Carthamustinctorius Flos (Hong‑hua), Angelicae Sinensis Radix Integra (Dang‑gui)a, c, d, Chuanxiong 
Rhizoma (Chuan‑xiong), Paeoniae Radix Alba (Bai‑shao)a, Rehmanniae Radix (Di‑huang)
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relieve AD-related symptoms, in addition to using stand-
ard anti-AD treatments.
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Table 5 Demographic characteristics of Bu–Zhong–Yi–Qi–Tang use among patients with Alzheimer’s disease
a  CM refers to traditional Chinese medicine
b  aOR refers to adjust odds ratio
c  CI refers to confidence interval
d  BPSD refers to behavioral and psychological symptoms of dementia
Characteristics Bu–Zhong–Yi–Qi–Tang users (%) CMa users not using Bu–Zhong–Yi–Qi–Tang (%) aORb (95 % CIc)
No. of cases 685 (77.1) 204 (22.9)
Age at diagnosis
 <45 5 (0.7) 2 (1) 0.69 (0.12–6.03)
 45–54 21 (3.1) 2 (1) 3.17 (0.70–17.44)
 55–64 88 (12.8) 22 (10.8) 1
 65–74 221 (32.1) 70 (34.3) 0.72 (0.23–1.34)
 75–84 304 (44.1) 92 (45.1) 0.92 (0.41–1.52)
 ≥85 45 (6.5) 16 (7.8) 0.64 (0.22–1.59)
Sex
 Female 377 (55.0) 99 (48.5) 1.23 (1.04–1.57)
 Male 308 (45.0) 104 (51.0) 1
Numbers of anti–Alzheimer’s or BPSD drugs
 1 26 (3.8) 11 (5.4) 1
 2 133 (19.4) 55 (27.0) 0.82 (0.21–2.01)
 3 259 (37.8) 75 (36.8) 1.32 (0.52–2.81)
 ≥4 367 (39.0) 63 (40.9) 1.04 (0.57–2.11)
Numbers of dementia BPSDd
 0 84 (12.3) 42 (20.6) 1
 1 115 (16.8) 63 (30.9) 0.72 (0.31–1.68)
 2 206 (30.1) 52 (25.5) 2.11 (0.93–3.38)
 ≥3 280 (40.9) 63 (30.9) 2.75 (0.82–4.31)
Numbers of comorbidity
 0 22 (3.2) 12 (5.9) 1
 1 90 (13.1) 35 (17.2) 1.21 (0.38–3.71)
 2 119 (17.4) 57 (27.9) 1.02 (0.31–4.23)
 ≥3 454 (66.3) 99 (48.5) 2.24 (0.71–4.55)
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